Utilisation des corticoïdes dans les infections cérébroméningées : Etude de bon usage
Keywords:
Corticoïdes, Infections cérébro-méningées, Bon usage
Abstract
Introduction : Dans les infections cérébro-méningées, les corticoïdes sont indiqués selon le germe, la gravité et le terrain. Lorsqu’ils sont prescrits dans le strict cadre d’indication, à la bonne posologie et pendant la durée requise, ils apportent un bénéfice thérapeutique évident. L’objectif de notre travail est d’évaluer le bon usage des corticoïdes dans les infections cérébro-méningées. Matériel et méthodes : Il s’agit d’une étude rétrospective sur une période d’un an, du 1er janvier au 31 décembre 2023 dans le service des maladies infectieuses du CHU IBN Rochd de Casablanca, portant sur les dossiers des patients hospitalisés pour une infection cérébrale et/ou méningée et ayant bénéficié d’une corticothérapie. La collecte des données a été effectuée grâce à une fiche d’enquête portant sur les données sociodémographiques, les caractéristiques cliniques et la corticothérapie. Résultats et conclusion : Trente-neuf cas ont été inclus. L’âge moyen de nos patients était de 39,87±15,85 ans avec une prédominance masculine. Vingt-cinq patients, soit 64,1%, ne présentaient aucun antécédent pathologique. Vingt-cinq patients (64,1%) avaient reçu une corticothérapie parentérale et orale, 25,64% une corticothérapie parentérale seule et 10,25% une corticothérapie orale seule. Au regard des recommandations de la Société Américaine de Maladies Infectieuses et de la Société de Pathologie Infectieuse de Langue Française, aucun des patients n’a reçu le corticoïde indiqué, à la dose et pendant la bonne durée de traitement. Cette étude met en lumière utilisation hospitalière inappropriée des corticoïdes dans les infections cérébro-méningées.
Introduction: In cerebrospinal infections, corticosteroids are indicated depending on the germ, severity, and the patient's condition. When prescribed strictly according to indications, at the correct dosage, and for the required duration, they provide a clear therapeutic benefit. The objective of our study is to evaluate the proper use of corticosteroids in cerebrospinal infections. Material and methods: This is a retrospective study over a one-year period, from January 1 to December 31, 2023 in the infectious diseases department of the IBN Rochd University Hospital in Casablanca, covering the files of patients hospitalized for a cerebral and/or meningeal infection and having benefited from corticosteroid therapy. Data collection was conducted using a survey form covering sociodemographic data, clinical characteristics, and corticosteroid therapy. Results and conclusion: Thirty-nine cases were included. The average age of our patients was 39.87±15.85 years, with a male predominance. Twenty-five patients, or 64.1%, had no pathological history. Twenty-five patients (64.1%) received both parenteral and oral corticosteroid therapy, 25.64% received only parenteral corticosteroid therapy, and 10.25% received only oral corticosteroid therapy. According to the recommendations of the Infectious Diseases Society of America and French Infectious Diseases Society, none of the patients received the correct molecule, at the right dose, and for the appropriate duration of treatment. This study highlights the inappropriate hospital use of corticosteroids in central nervous system infections.
Downloads
Download data is not yet available.
References
1. Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A. B., Kamali, A., Cuc, N. T., Binh, T. Q., Chau, N. V., Farrar, J., Merson, L., Phuong, L., Thwaites, G., Van Kinh, N., Thuy, P. T., Chierakul, W., Siriboon, S., Thiansukhon, E., Onsanit, S., Supphamongkholchaikul, W., Chan, A. K., … CryptoDex Investigators (2016). Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. The New England journal of medicine, 374(6), 542–554. https://doi.org/10.1056/NEJMoa1509024.
2. Belsey MA, Hoffpauir CW, & Smith MHD (1969). Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results. Pediatrics, 44:503-13 (https://doi.org/10.1542/peds.44.4.503).
3. Bhatt, S. M., Lauretano, A., Cabellos, C., Halpin, C., Levine, R. A., Xu, W. Z., Nadol, J. B., Jr, & Tuomanen, E. (1993). Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. The Journal of infectious diseases, 167(3), 675–683. https://doi.org/10.1093/infdis/167.3.675.
4. Bodilsen, J., D'Alessandris, Q. G., Humphreys, H., Iro, M. A., Klein, M., Last, K., Montesinos, I. L., Pagliano, P., Sipahi, O. R., San-Juan, R., Tattevin, P., Thurnher, M., de J Treviño-Rangel, R., Brouwer, M. C., & ESCMID Study Group for Infections of the Brain (ESGIB) (2024). European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 30(1), 66–89. https://doi.org/10.1016/j.cmi.2023.08.016.
5. Briot K, Bernard Cortet, Christian Roux, Laurence Fardet, Vered Abitbol, Justine Bacchetta, Daniel Buchon, Françoise Debiais, Pascal Guggenbuhl, Michel Laroche, Érik Legrand, Éric Lespessailles, Christian Marcelli, Georges Weryha, & Thierry Thomas, (2014). Actualisation 2014 des recommandations sur la prévention et le traitement de l’ostéoporose cortico-induite, Volume 4392, Issue 5, 10/2014, Pages 355-446, ISSN 1169-8330, http://dx.doi.org/10.1016/j.rhum.2014.07.009
6. Brouwer, M. C., McIntyre, P., Prasad, K., & van de Beek, D. (2015). Corticosteroids for acute bacterial meningitis. The Cochrane database of systematic reviews, 2015(9), CD004405. https://doi.org/10.1002/14651858.CD004405.pub5
7. Buttgereit, F., Brand, M. D., & Burmester, G. R. (1999). Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochemical pharmacology, 58(2), 363–368. https://doi.org/10.1016/s0006-2952(99)00090-8
8. Cassiano, L. M. G., Oliveira, M. D. S., de Queiroz, K. B., Amancio, A. M. T. D. S., Salim, A. C. M., Fernandes, G. D. R., Carneiro, C. M., & Coimbra, R. S. (2023). Uncovering the neuroprotective effect of vitamin B12 in pneumococcal meningitis: insights into its pleiotropic mode of action at the transcriptional level. Frontiers in immunology, 14, 1250055. https://doi.org/10.3389/fimmu.2023.1250055
9. Charlier, C., Perrodeau, É., Leclercq, A., Cazenave, B., Pilmis, B., Henry, B., Lopes, A., Maury, M. M., Moura, A., Goffinet, F., Dieye, H. B., Thouvenot, P., Ungeheuer, M. N., Tourdjman, M., Goulet, V., de Valk, H., Lortholary, O., Ravaud, P., Lecuit, M., & MONALISA, , (2017). Study group. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. The Lancet. Infectious diseases, 17(5), 510–519. https://doi.org/10.1016/S1473-3099(16)30521-7
10. Ciana, G., Parmar, N., Antonio, C., Pivetta, S., Tamburlini, G., & Cuttini, M. (1995). Effectiveness of adjunctive treatment with steroids in reducing short-term mortality in a high-risk population of children with bacterial meningitis. Journal of tropical pediatrics, 41(3), 164–168. https://doi.org/10.1093/tropej/41.3.164
11. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342899)
12. Davis, L. E., & Baldwin, N. G. (1999). Brain Abscess. Current treatment options in neurology, 1(2), 157–166. https://doi.org/10.1007/s11940-999-0015-7
13. DEFUENTES G., DUTASTA F., FICKO C. (2009) « DOSSIER - Corticothérapie générale ». Revue Du Praticien Medecine Generale. n°830, p. 741-745
14. de Gans, J., van de Beek, D., & European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators (2002). Dexamethasone in adults with bacterial meningitis. The New England journal of medicine, 347(20), 1549–1556. https://doi.org/10.1056/NEJMoa021334
15. DeLemos, R. A., & Haggerty, R. J. (1969). Corticosteroids as an adjunct to treatment in bacterial meningitis. A controlled clinical trial. Pediatrics, 44(1), 30–34
16. DUGAUQUIER, C., BATAILLE, Y., WILLEMS, E., FRÈRE, P., DE PRIJCK, B., BEGUIN, Y., BARON, F., (2009). TOXOPLASMOSE CÉRÉBRALE COMPLIQUANT UNE MINI-ALLOGREFFE DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES DU SANG PÉRIPHÉRIQUE, Rev Med Liège; 64 : 7-8 : 366-369
17. Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 152(4), 706–715. https://doi.org/10.1053/j.gastro.2017.01.031
18. Gijwani, D., Kumhar, M. R., Singh, V. B., Chadda, V. S., Soni, P. K., Nayak, K. C., & Gupta, B. K. (2002). Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. Neurology India, 50(1), 63–67
19. Girgis, N. I., Farid, Z., Mikhail, I. A., Farrag, I., Sultan, Y., & Kilpatrick, M. E. (1989). Dexamethasone treatment for bacterial meningitis in children and adults. The Pediatric infectious disease journal, 8(12), 848–851. https://doi.org/10.1097/00006454-198912000-00004
20. Gundamraj S & Hasbun R (2020) L'utilisation de stéroïdes adjuvants dans les infections du système nerveux central. Front. Cell. Infect. Microbiol. 10:592017. doi: 10.3389/fcimb.2020.592017
21. Haute Autorité de Santé. Les inhibiteurs de la pompe à protons chez l’adulte; 2009. Available from: https://www.has-sante. fr/jcms/r 1439925/fr/les-inhibiteurs-de-la-pompe-a-protons-chez-l-adulte
22. Hoefsloot, S., Urbanski, G., Lacout, C., Bouvard, B., & Lavigne, C. (2021). Quelles mesures adjuvantes associer à une corticothérapie orale prolongée dans le cadre des maladies inflammatoires ? Synthèse des recommandations françaises disponibles [Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations]. La Revue de medecine interne, 42(9), 616–624. https://doi.org/10.1016/j.revmed.2021.03.326
23. Kanra, G. Y., Ozen, H., Seçmeer, G., Ceyhan, M., Ecevit, Z., & Belgin, E. (1995). Beneficial effects of dexamethasone in children with pneumococcal meningitis. The Pediatric infectious disease journal, 14(6), 490–494. https://doi.org/10.1097/00006454-199506000-00005
24. Kilpi, T., Peltola, H., Jauhiainen, T., & Kallio, M. J. (1995). Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. The Finnish Study Group. The Pediatric infectious disease journal, 14(4), 270–278. https://doi.org/10.1097/00006454-199504000-00005
25. King, S. M., Law, B., Langley, J. M., Heurter, H., Bremner, D., Wang, E. E., & Gold, R. (1994). Dexamethasone therapy for bacterial meningitis: Better never than late?. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 5(5), 210–215. https://doi.org/10.1155/1994/257198
26. Koopmans, M. M., Brouwer, M. C., Bijlsma, M. W., Bovenkerk, S., Keijzers, W., van der Ende, A., & van de Beek, D. (2013). Listeria monocytogenes sequence type 6 and increased rate of unfavorable outcome in meningitis: epidemiologic cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57(2), 247–253. https://doi.org/10.1093/cid/cit250
27. Lebel, M. H., Freij, B. J., Syrogiannopoulos, G. A., Chrane, D. F., Hoyt, M. J., Stewart, S. M., Kennard, B. D., Olsen, K. D., & McCracken, G. H., Jr (1988). Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. The New England journal of medicine, 319(15), 964–971. https://doi.org/10.1056/NEJM198810133191502
28. Lebel, M. H., Hoyt, M. J., Waagner, D. C., Rollins, N. K., Finitzo, T., & McCracken, G. H., Jr (1989). Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis. American journal of diseases of children (1960), 143(3), 301–306. https://doi.org/10.1001/archpedi.1989.02150150055017
29. Lucht, F. (1996). Les méningites purulentes communautaires. Conférence de consensus. Med Mal Infect;26:944–51
30. Lutsar, I., Friedland, I. R., Jafri, H. S., Wubbel, L., Ahmed, A., Trujillo, M., McCoig, C. C., & McCracken, G. H., Jr (2003). Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. The Journal of antimicrobial chemotherapy, 52(4), 651–655. https://doi.org/10.1093/jac/dkg417
31. Martinez-Almoyna, L., De Broucker, T., Mailles, A., Stahl, J. P., & Scientific Committee of the French Guidelines on the Management of Infectious Encephalitis in Adults (2019). Management of infectious encephalitis in adults: Highlights from the French guidelines (short version). Revue neurologique, 175(7-8), 436–441. https://doi.org/10.1016/j.neurol.2019.07.009
32. Meyding-Lamadé, U., Jacobi, C., Martinez-Torres, F., Lenhard, T., Kress, B., Kieser, M., Klose, C., Einhäupl, K., Bösel, J., Mackert, M. B., Homberg, V., Koennecke, C., Weißheit, G., Claus, D., Kieseier, B., Bardutzky, J., Neumann-Haefelin, T., Lorenz, M. W., Steinmetz, H., Gerloff, C., … Craemer, E. (2019). The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial. Neurological research and practice, 1, 26. https://doi.org/10.1186/s42466-019-0031-3
33. Molyneux, E. M., Walsh, A. L., Forsyth, H., Tembo, M., Mwenechanya, J., Kayira, K., Bwanaisa, L., Njobvu, A., Rogerson, S., & Malenga, G. (2002). Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet (London, England), 360(9328), 211–218. https://doi.org/10.1016/s0140-6736(02)09458-8
34. Mustafa, M. M., Ramilo, O., Mertsola, J., Risser, R. C., Beutler, B., Hansen, E. J., & McCracken, G. H., Jr (1989). Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. The Journal of infectious diseases, 160(5), 818–825. https://doi.org/10.1093/infdis/160.5.818
35. Odio, C. M., Faingezicht, I., Paris, M., Nassar, M., Baltodano, A., Rogers, J., Sáez-Llorens, X., Olsen, K. D., & McCracken, G. H., Jr (1991). The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. The New England journal of medicine, 324(22), 1525–1531. https://doi.org/10.1056/NEJM199105303242201
36. Peltola, H., Roine, I., Fernández, J., Zavala, I., Ayala, S. G., Mata, A. G., Arbo, A., Bologna, R., Miño, G., Goyo, J., López, E., de Andrade, S. D., & Sarna, S. (2007). Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45(10), 1277–1286. https://doi.org/10.1086/522534
37. Philippart, F., (2006). Place de la corticothérapie dans l'arsenal thérapeutique aux urgences: mise au point, Réanimation,Volume 15, Issues 7–8, Pages 533-539, ISSN 1624-0693, https://doi.org/10.1016/j.reaurg.2006.10.008.(https://www.sciencedirect.com/science/article/pii/S1624069306001496)
38. Porta, S., Danza, A., Arias Saavedra, M., Carlomagno, A., Goizueta, M. C., Vivero, F., & Ruiz-Irastorza, G. (2020). Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of clinical medicine, 9(9), 2709. https://doi.org/10.3390/jcm9092709
39. Reid, I. R., Bristow, S. M., & Bolland, M. J. (2015). Calcium supplements: benefits and risks. Journal of internal medicine, 278(4), 354–368. https://doi.org/10.1111/joim.12394
40. Report of a workshop: Pathophysiology of bacterial memingitis-- implications for new management strategies. (1987). The Pediatric infectious disease journal, 6(12), 1143–1171
41. Sáez-Llorens, X., Jafari, H. S., Severien, C., Parras, F., Olsen, K. D., Hansen, E. J., Singer, I. I., & McCracken, G. H., Jr (1991). Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis. The Journal of clinical investigation, 88(6), 2003–2011. https://doi.org/10.1172/JCI115527
42. Sankar, J., Singhi, P., Bansal, A., Ray, P., & Singhi, S. (2007). Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian pediatrics, 44(9), 649–656
43. Schaad, U. B., Lips, U., Gnehm, H. E., Blumberg, A., Heinzer, I., & Wedgwood, J. (1993). Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet (London, England), 342(8869), 457–461. https://doi.org/10.1016/0140-6736(93)91592-a
44. Stahl, J. P., Azouvi, P., Bruneel, F., De Broucker, T., Duval, X., Fantin, B., Girard, N., Herrmann, J. L., Honnorat, J., Lecuit, M., Mailles, A., Martinez-Almoyna, L., Morand, P., Piroth, L., Tattevin, P., & reviewing group (2017). Guidelines on the management of infectious encephalitis in adults. Medecine et maladies infectieuses, 47(3), 179–194. https://doi.org/10.1016/j.medmal.2017.01.005
45. Strehl, C., & Buttgereit, F. (2014). Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Annals of the New York Academy of Sciences, 1318, 1–6. https://doi.org/10.1111/nyas.12364
46. Täuber, M. G., Brooks-Fournier, R. A., & Sande, M. A. (1986). Experimental models of CNS infections. Contributions to concepts of disease and treatment. Neurologic clinics, 4(1), 249–264
47. Thomas, R., Le Tulzo, Y., Bouget, J., Camus, C., Michelet, C., Le Corre, P., & Bellissant, E. (1999). Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive care medicine, 25(5), 475–480. https://doi.org/10.1007/s001340050883
48. Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004). Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39(9), 1267–1284. https://doi.org/10.1086/425368
49. van de Beek D. (2009). Corticosteroids for acute adult bacterial meningitis. Medecine et maladies infectieuses, 39(7-8), 531–538. https://doi.org/10.1016/j.medmal.2009.02.033
50. van der Flier, M., Geelen, S. P., Kimpen, J. L., Hoepelman, I. M., & Tuomanen, E. I. (2003). Reprogramming the host response in bacterial meningitis: how best to improve outcome?. Clinical microbiology reviews, 16(3), 415–429. https://doi.org/10.1128/CMR.16.3.415-429.2003
51. Wald, E. R., Kaplan, S. L., Mason, E. O., Jr, Sabo, D., Ross, L., Arditi, M., Wiedermann, B. L., Barson, W., Kim, K. S., & Yogov, R. (1995). Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics, 95(1), 21–28
52. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/353829)
53. WHO guidelines on meningitis diagnosis, treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.
2. Belsey MA, Hoffpauir CW, & Smith MHD (1969). Dexamethasone in the treatment of acute bacterial meningitis: the effect of study design on the interpretation of results. Pediatrics, 44:503-13 (https://doi.org/10.1542/peds.44.4.503).
3. Bhatt, S. M., Lauretano, A., Cabellos, C., Halpin, C., Levine, R. A., Xu, W. Z., Nadol, J. B., Jr, & Tuomanen, E. (1993). Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. The Journal of infectious diseases, 167(3), 675–683. https://doi.org/10.1093/infdis/167.3.675.
4. Bodilsen, J., D'Alessandris, Q. G., Humphreys, H., Iro, M. A., Klein, M., Last, K., Montesinos, I. L., Pagliano, P., Sipahi, O. R., San-Juan, R., Tattevin, P., Thurnher, M., de J Treviño-Rangel, R., Brouwer, M. C., & ESCMID Study Group for Infections of the Brain (ESGIB) (2024). European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 30(1), 66–89. https://doi.org/10.1016/j.cmi.2023.08.016.
5. Briot K, Bernard Cortet, Christian Roux, Laurence Fardet, Vered Abitbol, Justine Bacchetta, Daniel Buchon, Françoise Debiais, Pascal Guggenbuhl, Michel Laroche, Érik Legrand, Éric Lespessailles, Christian Marcelli, Georges Weryha, & Thierry Thomas, (2014). Actualisation 2014 des recommandations sur la prévention et le traitement de l’ostéoporose cortico-induite, Volume 4392, Issue 5, 10/2014, Pages 355-446, ISSN 1169-8330, http://dx.doi.org/10.1016/j.rhum.2014.07.009
6. Brouwer, M. C., McIntyre, P., Prasad, K., & van de Beek, D. (2015). Corticosteroids for acute bacterial meningitis. The Cochrane database of systematic reviews, 2015(9), CD004405. https://doi.org/10.1002/14651858.CD004405.pub5
7. Buttgereit, F., Brand, M. D., & Burmester, G. R. (1999). Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochemical pharmacology, 58(2), 363–368. https://doi.org/10.1016/s0006-2952(99)00090-8
8. Cassiano, L. M. G., Oliveira, M. D. S., de Queiroz, K. B., Amancio, A. M. T. D. S., Salim, A. C. M., Fernandes, G. D. R., Carneiro, C. M., & Coimbra, R. S. (2023). Uncovering the neuroprotective effect of vitamin B12 in pneumococcal meningitis: insights into its pleiotropic mode of action at the transcriptional level. Frontiers in immunology, 14, 1250055. https://doi.org/10.3389/fimmu.2023.1250055
9. Charlier, C., Perrodeau, É., Leclercq, A., Cazenave, B., Pilmis, B., Henry, B., Lopes, A., Maury, M. M., Moura, A., Goffinet, F., Dieye, H. B., Thouvenot, P., Ungeheuer, M. N., Tourdjman, M., Goulet, V., de Valk, H., Lortholary, O., Ravaud, P., Lecuit, M., & MONALISA, , (2017). Study group. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. The Lancet. Infectious diseases, 17(5), 510–519. https://doi.org/10.1016/S1473-3099(16)30521-7
10. Ciana, G., Parmar, N., Antonio, C., Pivetta, S., Tamburlini, G., & Cuttini, M. (1995). Effectiveness of adjunctive treatment with steroids in reducing short-term mortality in a high-risk population of children with bacterial meningitis. Journal of tropical pediatrics, 41(3), 164–168. https://doi.org/10.1093/tropej/41.3.164
11. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update edition. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342899)
12. Davis, L. E., & Baldwin, N. G. (1999). Brain Abscess. Current treatment options in neurology, 1(2), 157–166. https://doi.org/10.1007/s11940-999-0015-7
13. DEFUENTES G., DUTASTA F., FICKO C. (2009) « DOSSIER - Corticothérapie générale ». Revue Du Praticien Medecine Generale. n°830, p. 741-745
14. de Gans, J., van de Beek, D., & European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators (2002). Dexamethasone in adults with bacterial meningitis. The New England journal of medicine, 347(20), 1549–1556. https://doi.org/10.1056/NEJMoa021334
15. DeLemos, R. A., & Haggerty, R. J. (1969). Corticosteroids as an adjunct to treatment in bacterial meningitis. A controlled clinical trial. Pediatrics, 44(1), 30–34
16. DUGAUQUIER, C., BATAILLE, Y., WILLEMS, E., FRÈRE, P., DE PRIJCK, B., BEGUIN, Y., BARON, F., (2009). TOXOPLASMOSE CÉRÉBRALE COMPLIQUANT UNE MINI-ALLOGREFFE DE CELLULES SOUCHES HÉMATOPOÏÉTIQUES DU SANG PÉRIPHÉRIQUE, Rev Med Liège; 64 : 7-8 : 366-369
17. Freedberg, D. E., Kim, L. S., & Yang, Y. X. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology, 152(4), 706–715. https://doi.org/10.1053/j.gastro.2017.01.031
18. Gijwani, D., Kumhar, M. R., Singh, V. B., Chadda, V. S., Soni, P. K., Nayak, K. C., & Gupta, B. K. (2002). Dexamethasone therapy for bacterial meningitis in adults: a double blind placebo control study. Neurology India, 50(1), 63–67
19. Girgis, N. I., Farid, Z., Mikhail, I. A., Farrag, I., Sultan, Y., & Kilpatrick, M. E. (1989). Dexamethasone treatment for bacterial meningitis in children and adults. The Pediatric infectious disease journal, 8(12), 848–851. https://doi.org/10.1097/00006454-198912000-00004
20. Gundamraj S & Hasbun R (2020) L'utilisation de stéroïdes adjuvants dans les infections du système nerveux central. Front. Cell. Infect. Microbiol. 10:592017. doi: 10.3389/fcimb.2020.592017
21. Haute Autorité de Santé. Les inhibiteurs de la pompe à protons chez l’adulte; 2009. Available from: https://www.has-sante. fr/jcms/r 1439925/fr/les-inhibiteurs-de-la-pompe-a-protons-chez-l-adulte
22. Hoefsloot, S., Urbanski, G., Lacout, C., Bouvard, B., & Lavigne, C. (2021). Quelles mesures adjuvantes associer à une corticothérapie orale prolongée dans le cadre des maladies inflammatoires ? Synthèse des recommandations françaises disponibles [Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations]. La Revue de medecine interne, 42(9), 616–624. https://doi.org/10.1016/j.revmed.2021.03.326
23. Kanra, G. Y., Ozen, H., Seçmeer, G., Ceyhan, M., Ecevit, Z., & Belgin, E. (1995). Beneficial effects of dexamethasone in children with pneumococcal meningitis. The Pediatric infectious disease journal, 14(6), 490–494. https://doi.org/10.1097/00006454-199506000-00005
24. Kilpi, T., Peltola, H., Jauhiainen, T., & Kallio, M. J. (1995). Oral glycerol and intravenous dexamethasone in preventing neurologic and audiologic sequelae of childhood bacterial meningitis. The Finnish Study Group. The Pediatric infectious disease journal, 14(4), 270–278. https://doi.org/10.1097/00006454-199504000-00005
25. King, S. M., Law, B., Langley, J. M., Heurter, H., Bremner, D., Wang, E. E., & Gold, R. (1994). Dexamethasone therapy for bacterial meningitis: Better never than late?. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 5(5), 210–215. https://doi.org/10.1155/1994/257198
26. Koopmans, M. M., Brouwer, M. C., Bijlsma, M. W., Bovenkerk, S., Keijzers, W., van der Ende, A., & van de Beek, D. (2013). Listeria monocytogenes sequence type 6 and increased rate of unfavorable outcome in meningitis: epidemiologic cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57(2), 247–253. https://doi.org/10.1093/cid/cit250
27. Lebel, M. H., Freij, B. J., Syrogiannopoulos, G. A., Chrane, D. F., Hoyt, M. J., Stewart, S. M., Kennard, B. D., Olsen, K. D., & McCracken, G. H., Jr (1988). Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. The New England journal of medicine, 319(15), 964–971. https://doi.org/10.1056/NEJM198810133191502
28. Lebel, M. H., Hoyt, M. J., Waagner, D. C., Rollins, N. K., Finitzo, T., & McCracken, G. H., Jr (1989). Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis. American journal of diseases of children (1960), 143(3), 301–306. https://doi.org/10.1001/archpedi.1989.02150150055017
29. Lucht, F. (1996). Les méningites purulentes communautaires. Conférence de consensus. Med Mal Infect;26:944–51
30. Lutsar, I., Friedland, I. R., Jafri, H. S., Wubbel, L., Ahmed, A., Trujillo, M., McCoig, C. C., & McCracken, G. H., Jr (2003). Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. The Journal of antimicrobial chemotherapy, 52(4), 651–655. https://doi.org/10.1093/jac/dkg417
31. Martinez-Almoyna, L., De Broucker, T., Mailles, A., Stahl, J. P., & Scientific Committee of the French Guidelines on the Management of Infectious Encephalitis in Adults (2019). Management of infectious encephalitis in adults: Highlights from the French guidelines (short version). Revue neurologique, 175(7-8), 436–441. https://doi.org/10.1016/j.neurol.2019.07.009
32. Meyding-Lamadé, U., Jacobi, C., Martinez-Torres, F., Lenhard, T., Kress, B., Kieser, M., Klose, C., Einhäupl, K., Bösel, J., Mackert, M. B., Homberg, V., Koennecke, C., Weißheit, G., Claus, D., Kieseier, B., Bardutzky, J., Neumann-Haefelin, T., Lorenz, M. W., Steinmetz, H., Gerloff, C., … Craemer, E. (2019). The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial. Neurological research and practice, 1, 26. https://doi.org/10.1186/s42466-019-0031-3
33. Molyneux, E. M., Walsh, A. L., Forsyth, H., Tembo, M., Mwenechanya, J., Kayira, K., Bwanaisa, L., Njobvu, A., Rogerson, S., & Malenga, G. (2002). Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet (London, England), 360(9328), 211–218. https://doi.org/10.1016/s0140-6736(02)09458-8
34. Mustafa, M. M., Ramilo, O., Mertsola, J., Risser, R. C., Beutler, B., Hansen, E. J., & McCracken, G. H., Jr (1989). Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. The Journal of infectious diseases, 160(5), 818–825. https://doi.org/10.1093/infdis/160.5.818
35. Odio, C. M., Faingezicht, I., Paris, M., Nassar, M., Baltodano, A., Rogers, J., Sáez-Llorens, X., Olsen, K. D., & McCracken, G. H., Jr (1991). The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. The New England journal of medicine, 324(22), 1525–1531. https://doi.org/10.1056/NEJM199105303242201
36. Peltola, H., Roine, I., Fernández, J., Zavala, I., Ayala, S. G., Mata, A. G., Arbo, A., Bologna, R., Miño, G., Goyo, J., López, E., de Andrade, S. D., & Sarna, S. (2007). Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45(10), 1277–1286. https://doi.org/10.1086/522534
37. Philippart, F., (2006). Place de la corticothérapie dans l'arsenal thérapeutique aux urgences: mise au point, Réanimation,Volume 15, Issues 7–8, Pages 533-539, ISSN 1624-0693, https://doi.org/10.1016/j.reaurg.2006.10.008.(https://www.sciencedirect.com/science/article/pii/S1624069306001496)
38. Porta, S., Danza, A., Arias Saavedra, M., Carlomagno, A., Goizueta, M. C., Vivero, F., & Ruiz-Irastorza, G. (2020). Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. Journal of clinical medicine, 9(9), 2709. https://doi.org/10.3390/jcm9092709
39. Reid, I. R., Bristow, S. M., & Bolland, M. J. (2015). Calcium supplements: benefits and risks. Journal of internal medicine, 278(4), 354–368. https://doi.org/10.1111/joim.12394
40. Report of a workshop: Pathophysiology of bacterial memingitis-- implications for new management strategies. (1987). The Pediatric infectious disease journal, 6(12), 1143–1171
41. Sáez-Llorens, X., Jafari, H. S., Severien, C., Parras, F., Olsen, K. D., Hansen, E. J., Singer, I. I., & McCracken, G. H., Jr (1991). Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis. The Journal of clinical investigation, 88(6), 2003–2011. https://doi.org/10.1172/JCI115527
42. Sankar, J., Singhi, P., Bansal, A., Ray, P., & Singhi, S. (2007). Role of dexamethasone and oral glycerol in reducing hearing and neurological sequelae in children with bacterial meningitis. Indian pediatrics, 44(9), 649–656
43. Schaad, U. B., Lips, U., Gnehm, H. E., Blumberg, A., Heinzer, I., & Wedgwood, J. (1993). Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet (London, England), 342(8869), 457–461. https://doi.org/10.1016/0140-6736(93)91592-a
44. Stahl, J. P., Azouvi, P., Bruneel, F., De Broucker, T., Duval, X., Fantin, B., Girard, N., Herrmann, J. L., Honnorat, J., Lecuit, M., Mailles, A., Martinez-Almoyna, L., Morand, P., Piroth, L., Tattevin, P., & reviewing group (2017). Guidelines on the management of infectious encephalitis in adults. Medecine et maladies infectieuses, 47(3), 179–194. https://doi.org/10.1016/j.medmal.2017.01.005
45. Strehl, C., & Buttgereit, F. (2014). Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Annals of the New York Academy of Sciences, 1318, 1–6. https://doi.org/10.1111/nyas.12364
46. Täuber, M. G., Brooks-Fournier, R. A., & Sande, M. A. (1986). Experimental models of CNS infections. Contributions to concepts of disease and treatment. Neurologic clinics, 4(1), 249–264
47. Thomas, R., Le Tulzo, Y., Bouget, J., Camus, C., Michelet, C., Le Corre, P., & Bellissant, E. (1999). Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Intensive care medicine, 25(5), 475–480. https://doi.org/10.1007/s001340050883
48. Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004). Practice guidelines for the management of bacterial meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39(9), 1267–1284. https://doi.org/10.1086/425368
49. van de Beek D. (2009). Corticosteroids for acute adult bacterial meningitis. Medecine et maladies infectieuses, 39(7-8), 531–538. https://doi.org/10.1016/j.medmal.2009.02.033
50. van der Flier, M., Geelen, S. P., Kimpen, J. L., Hoepelman, I. M., & Tuomanen, E. I. (2003). Reprogramming the host response in bacterial meningitis: how best to improve outcome?. Clinical microbiology reviews, 16(3), 415–429. https://doi.org/10.1128/CMR.16.3.415-429.2003
51. Wald, E. R., Kaplan, S. L., Mason, E. O., Jr, Sabo, D., Ross, L., Arditi, M., Wiedermann, B. L., Barson, W., Kim, K. S., & Yogov, R. (1995). Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics, 95(1), 21–28
52. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://iris.who.int/ handle/10665/353829)
53. WHO guidelines on meningitis diagnosis, treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.
Published
2025-11-12
How to Cite
Dossou-Yovo, V. R., Ghicha, I., Banid, A., Rahmoune, I., Majambere, J.- claude, Mwanayile, H., Ouggane, I., Filali, H., & El Filali, K. M. (2025). Utilisation des corticoïdes dans les infections cérébroméningées : Etude de bon usage. European Scientific Journal, ESJ, 47, 1. Retrieved from https://eujournal.org/index.php/esj/article/view/20303
Section
ESI Preprints
Copyright (c) 2025 Vigniako Roussaint Dossou-Yovo, Ikram Ghicha, Afaf Banid, Imane Rahmoune, Jean-claude Majambere, Hassan Mwanayile, Inas Ouggane, Houda Filali, Kamal Marhoum El Filali
This work is licensed under a Creative Commons Attribution 4.0 International License.
